Skip to main content
Log in

Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments

Imaging diagnosis and staging of hepatocellular carcinoma

  • Topics
  • Hepatocellular carcinoma: Eastern and Western experiences
  • Published:
Journal of Hepato-Biliary-Pancreatic Sciences

Abstract

Diagnostic confirmation and assessment of disease extent are crucial for proper management of patients with hepatocellular carcinoma (HCC). Imaging studies play a crucial role in the diagnosis and staging of HCC. The imaging techniques commonly used for the diagnosis of HCC include ultrasound, computed tomography, and magnetic resonance imaging. Currently, improvements in imaging technology make a noninvasive and reliable diagnostic assessment of hepatocellular nodules possible in the cirrhotic liver. Biopsy is infrequently required prior to treatment, and the diagnosis of HCC is strongly dependent on hemodynamic features (arterial hypervascularity and washout in the venous phase) on dynamic imaging. Accurate staging of HCC is important in determining prognosis and in deciding optimal treatment for each patient. In addition, although there is a strong demand for an accurate diagnostic tool to detect smaller tumors, until now, the major challenge for radiologists in imaging cirrhosis is the characterization of small hepatocellular nodules in the cirrhotic liver. Further improvement of imaging technologies including functional imaging such as elastography, perfusion imaging and diffusion imaging, and development of new contrast media will undoubtedly improve the detection and characterization of small tumors. In this article, we present a summary of the most recent information on the diagnosis and staging of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Bruix J, Sherman M, Management of Hepatocellular Carcinoma. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Hepatology. 2005;42:1208–36.

    Article  PubMed  Google Scholar 

  2. Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis. 2005;9:235–51.

    Article  PubMed  Google Scholar 

  3. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.

    Article  PubMed  Google Scholar 

  4. Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311–30.

    Article  PubMed  Google Scholar 

  5. Choi BI. The current status of imaging diagnosis of hepatocellular carcinoma. Liver Transpl. 2004;10:S20–5.

    Article  PubMed  Google Scholar 

  6. Miller G, Schwartz LH, D’Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am. 2007;16:343–68.

    Article  PubMed  Google Scholar 

  7. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance and alph-fetoprotein in diagnosing hepatocellular carcinoma: a systemic review. Am J Gastroenterol. 2006;101:513–23.

    Article  CAS  PubMed  Google Scholar 

  8. Tanaka S, Kitamra T, Fujita M, Kasugai H, Inoue A, Ishiguro S. Small hepatocellular carcinoma: differentiation from adenomatous hyperplastic nodule with color Doppler flow imaging. Radiology. 1992;182:161–5.

    CAS  PubMed  Google Scholar 

  9. Wilson SR, Burns PN. An algorithm for the diagnosis of focal liver masses using microbubble contrast-enhanced pulse-inversion sonography. AJR. 2006;186:1401–12.

    Article  PubMed  Google Scholar 

  10. Hatanaka K, Kudo M, Minami Y, et al. Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology. 2008;51(Suppl 1):61–9.

    Article  PubMed  Google Scholar 

  11. Fahey BJ, Nelson RC, Bradway DP, Hsu SJ, Dumont DM, Trahey GE. In vivo visualization of abdominal malignancies with acoustic radiation force elastography. Phys Med Biol. 2008;53:279–93.

    Article  CAS  PubMed  Google Scholar 

  12. Zech CJ, Reiser MF, Herrmann KA. Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance imaging: state of the art. Dig Dis. 2009;27:114–24.

    Article  PubMed  Google Scholar 

  13. Lencioni R, Cioni D, Pina CD, Crocetti L, Bartolozzi C. Hepatocellular carcinoma: imaging diagnosis. Seminar Liver Disease. 2005;25:162–70.

    Article  Google Scholar 

  14. Iannaccone R, Laghi A, Catalano C, et al. Hepatocellular carcinoma: role of unenhanced and delayed-phase multi-detector row helical CT in patients with cirrhosis. Radiology. 2005;234:460–7.

    Article  PubMed  Google Scholar 

  15. Kim SH, Choi BI, Lee JY, et al. Diagnostic accuracy of multi-/single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the Milan Criteria before liver transplantation. Intervirology. 2008;51(Suppl 1):52–60.

    Article  PubMed  Google Scholar 

  16. Ariff B, Lloyd CR, Khan S, et al. Imaging of liver cancer. World J Gastroenterol. 2009;15:1289–300.

    Article  PubMed  Google Scholar 

  17. Brancatelli G, Baron RL, Peterson MS, Marsh W. Helical CT screening for hepatocellular carcinoma in patients with cirrhosis: frequency and causes of false-positive interpretation. AJR Am J Roentgenol. 2003;180:1007–14.

    PubMed  Google Scholar 

  18. Sahani DV, Holalkere NS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue–initial experience. Radiology. 2007;243:736–43.

    Article  PubMed  Google Scholar 

  19. Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncology. 2008;13:120–5.

    Article  CAS  Google Scholar 

  20. Marrero JA, Hussain HK, Nghiem HV, et al. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterial enhancing liver mass. Liver Transpl. 2005;11:281–9.

    Article  PubMed  Google Scholar 

  21. Kim YK, Kim CS, Chung GH, et al. Comparison of gadobenate dimeglumine-enhanced dynamic MRI and 16-MDCT for the detection of hepatocellular carcinoma. AJR. 2006;186:149–57.

    Article  PubMed  Google Scholar 

  22. Ebara M, Ohto M, Watanabe Y, et al. Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies. Radiology. 1986;159:371–7.

    CAS  PubMed  Google Scholar 

  23. Kim YK, Kim CS, Kwak HS, Lee JM. Three dimensional dynamic liver MRI imaging using sensitivity encoding for detection of hepatocellular carcinomas; comparison with superparamagnetic rion oxide-enhanced MR imaging. J Magn Reson Imaging. 2004;20:826–37.

    Article  PubMed  Google Scholar 

  24. Youk JH, Lee JM, Kim CS. MRI for detection of hepatocellular carcinoma: comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents. AJR Am J Roentgenol. 2004;183:1049–54.

    PubMed  Google Scholar 

  25. Yoo HJ, Lee JM, Lee MW, et al. Hepatocellular carcinoma in cirrhotic liver: double-contrast-enhanced, high-resolution 3.0T-MR imaging with pathologic correlation. Invest Radiol. 2008;43:538–46.

    Article  PubMed  Google Scholar 

  26. Kim JI, Lee JM, Choi JY, et al. The value of gadobenate dimeglumine-enhanced delayed-phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol. 2008;43:202–10.

    Article  CAS  PubMed  Google Scholar 

  27. Marin D, Di Martino M, Guerrisi A, De Filippis G, Rossi M, Ginanni Corradini S, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology. 2009;251:85–95.

    Article  PubMed  Google Scholar 

  28. Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR. 2009;192:1675–81.

    Article  PubMed  Google Scholar 

  29. Bartolozzi C, Crocetti L, Lencioni R, et al. Biliary and reticuloendothelial impairment in hepatocarcinogenesis: the diagnostic role of tissue-specific MR contrast media. Eur Radiol. 2007;17:2519–30.

    Article  PubMed  Google Scholar 

  30. Greene FL, Page DL, Fleming ID, Firtz A, Balch CM, Haller DG, Morrow M. AJCC cancer staging manual. 6th ed. Chicago: Springer; 2002. 435 p.

  31. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer. 1985;56:918–28.

    Article  CAS  PubMed  Google Scholar 

  32. The cancer of the liver italian program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology. 1998;28:751–5.

    Article  Google Scholar 

  33. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005;41:707–16.

    Article  PubMed  Google Scholar 

  34. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Byung Ihn Choi.

About this article

Cite this article

Choi, B.I., Lee, J.M. Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments. J Hepatobiliary Pancreat Sci 17, 369–373 (2010). https://doi.org/10.1007/s00534-009-0227-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00534-009-0227-y

Keywords

Navigation